. 28 Año 9 (2012) enero-abril. Señales de humo

- Editorial por Hugo Reynoso Urtiz. - Fin del Mundo por Guadalupe Sánchez, Vance Holliday, Natalia Martínez e Ismael Sánchez. - Hallazgos arqueológicos en la Sierra de Santa Úrsula. Un ejemplo de colaboración institucional por César A. Quijada López y Tomás Pérez Reyes. - Ocho Pueblos Yaquis por Raquel Padilla Ramos. - Cementerio prehispánico en el sureste de Sonora por Cristina García Moreno. - Seguimos caminando. Estudio de factibilidad del Libramiento Hermosillo por César A. Quijada López, Júpiter Martínez y Daí Blanquel G. - Trabajos de conservación en el sitio arqueológico La Pintada por Eréndida Contreras Barragán. - Estudio de los imaginarios sociales en los pueblos indígenas de Sonora en la larga duración por Esperanza Donjuan Espinoza. - Los guarijío: un mundo distante por Alejandro Aguilar Zeleny. - La Biblioteca informa por Guadalupe Piña Ortiz. - Una vida entre libros Guadalupe Piña Ortiz por Juilo César Montané Martí

A Workshop on Measuring the Progression of Atrophy Secondary to Stargardt Disease in the ProgStar Studies: Findings and Lessons Learned

The Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies were designed to measure the progression of Stargardt disease through the use of fundus autofluorescence imaging, optical coherence tomography, and microperimetry. The overarching objectives of the studies were to document the natural course of Stargardt disease and identify the most appropriate clinical outcome measures for clinical trials assessing the efficacy and safety of upcoming treatments for Stargardt disease. A workshop organized by the Foundation Fighting Blindness Clinical Research Institute was held on June 11, 2018, in Baltimore, MD, USA. Invited speakers discussed spectral-domain optical coherence tomography, fundus autofluorescence, and microperimetry methods and findings in the ProgStar prospective study. The workshop concluded with a panel discussion of optimal endpoints for measuring treatment efficacy in Stargardt disease. We summarize the workshop presentations in light of the most current literature on Stargardt disease and discuss potential clinical outcome measures and endpoints for future treatment trials